17 Jun, 2021, 21:23 ET
NEW YORK, June 17, 2021 /PRNewswire/ --
The endocrinology drugs market is expected to grow by USD 25.25 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the endocrinology drugs market in optimistic, probable, and pessimistic forecast scenarios.
Request a Free Sample to understand the scope of the report
The endocrinology drugs market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.
With the continuing spread of the coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renewal phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.
Key Considerations for Market Forecast:
- Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
- Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
- Pre- as well as post-COVID-19 market estimates
- Quarterly impact analysis and updates on market estimates
The endocrinology drugs market is driven by the increase in the incidence of endocrine disorders. In addition, ongoing research in novel dosage formulations and drug delivery systems are expected to trigger the endocrinology drugs market toward witnessing a CAGR of over 6% during the forecast period.
Gain more insights about the global trends impacting the future of the endocrinology drugs market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR40785
Major Five Endocrinology Drugs Market Participants:
Acerus Pharmaceuticals Corp.: The company offers a wide range of endocinology drugs such as Natesto, Estrace, and others.
Beta Cell NV: The company offers endocrinology drugs for type 1 diabetes called the Betacraft.
Eli Lilly and Co.: The company offers Endocrinology products such as Basaglar, Evista, Forteo, Glyxambi, humalog, and others.
Novo Nordisk AS: The company offers Norditropin, Norditropin flexPro, Norditropin Nordiflex, Norditropin Nordilet, and others.
Sanofi SA: The company offers endocrinology products such as Rare Disease Therapy Caprelsa and others.
Endocrinology Drugs Market 2021-2025: Segmentation
Endocrinology drugs market is segmented as below:
- North America
- Therapy Area
- Diabetes Drugs
- Thyroid Hormone Disorders
Gain instant access to 17,000+ market research reports by using
Technavio's SUBSCRIPTION platform
Related Reports on Healthcare Include:
Global Endovenous Ablation Devices Market - Global endovenous ablation devices market is segmented by product (EVLT devices, RFA devices, and NTNT devices) and geography (North America, Europe, Asia, and ROW).
Request a Free Sample Report
Global Neuroendovascular Coils Market- Global neuroendovascular coils market is segmented by Product (GDC and Matrix coil) and Geography (North America, Europe, Asia, and ROW).
Request a Free Sample Report
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Share this article